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Abstract 
Polyurethanes (PUs), formed by the reaction of diisocyanates with polyols (or equivalent) in the 
presence of a catalyst, have a wide variety of industrial uses. Much recent attention has focused on 
their biomedical applications, owing to their biocompatibility, biodegradability and tailorable 
chemical and physical forms. Examples of such application areas include antibacterial surfaces and 
catheters, drug delivery vehicles, stents, surgical dressings/pressure sensitive adhesives, tissue 
engineering scaffolds and electrospinning, nerve generation, cardiac patches and PU coatings for 
breast implants. Following a brief introduction to PUs, this review surveys selected articles, mostly 
from 2014 to 2017, that highlight this diverse range of biomedical applications offered by PU 
materials and coatings. 
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Abbreviations 
BD  1,4′-Butanediol 
ECM  Extra cellular matrix 
HMDI  4,4′-Dicyclohexylmethane diisocyanate 
HDI  1,6-Hexamethylene diisocyanate 
IPDI  Isophorone diisocyanate 
MDI  4,4′-Methylene diphenyl diisocyanate 
PCL  Polycaprolactone 
PECUU Poly(ester carbonate urethane)urea 
PEG  Polyethylene glycol 
PEP  Polyester polyols 
PLA  Polylactide 
PLGA  Polylactic-co-glycolic acid 
PPG  Polypropylene glycol 
PTMEG Polytetramethylene ether glycol 
PU  Polyurethane 
PUS  PurSil®AL20 
REACH Registration, Evaluation, Authorisation and Restriction of Chemicals 
RoHS  Restriction of the use of certain Hazardous Substances 
TDI  Toluene diisocyanate 
TPU  Thermoplastic polyurethane 
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Introduction 
 
Polyurethanes (PUs) were invented by Professor Dr Otto Bayer in the 1930s, building on a reaction 
discovered in 1849 that alcohols can react with isocyanates to produce urethane (carbamate) groups.1 
By the 1950s, PUs were finding a diverse range of applications, including coatings, adhesives, rigid 
foams, and elastomers.2 Today, PUs are one of the most versatile class of materials,3 finding an ever-
increasing range of applications in many manufacturing sectors; annual production in 2015 had 
reached over 18 million tons.4  
 
Coatings form a significant proportion of PU’s applications (perhaps ∼10%). Examples include PU 
paints (for steel, concrete, wood and other surfaces),5,6 and coatings for automotive interiors,7 
automotive acid-rain etching-resistant topcoats and clearcoats,8 aircraft,8 industrial machinery,9 
adhesives,10 marine applications11,12 and many others. PU is applied as coatings using various 
methodologies, such aspowder coatings, dip-coating, spray, roller, curtain-coater or electrostatic 
application.8,13 Reasons for the use of PU coatings include high-performance characteristics, such as 
durable finish, flexibility, toughness, strength, abrasion, corrosion, chemical and stain resistance, good 
light stability when aliphatic isocyanates are used, high gloss with exceptional UV protection 
characteristics and good low temperature properties.5,6,8,14 The latter factor is an important reason for 
the use of PU coatings on plastic substrates, including topcoats to epoxy surfaces.12 
 
In an excellent review published in 1999, Zdrahala & Zdrahala describe the historical development of 
the science and application of PUs in the biomedical arena.15 These authors state that it was perhaps a 
paper appearing in Science in 1967 describing the use of a "medical-grade" elastomer16 that brought 
PUs for biomedical applications into the spotlight. 
 
This article reviews a number of papers, mostly from 2014-2017, that highlight the diverse range of 
biomedical applications offered by PUs, following an introduction into their chemistry and properties. 
 
The chemistry of PUs 
 
PUs are produced by the addition polymerisation of an isocyanate (generally a diisocyanate), derived 
from crude oil, and a polyol (polyether or polyester, or similar), often in the presence of a catalyst and 
a chain extender to form the desired polymer (Fig. 1).17 Additives, such as fillers, degassing agents, 
moisture scavengers and pigments, are also often included. 
 
Diisocyanates 
 
Diisocyanates are isocyanates containing two –N=C=O (NCO) groups per molecule.17,18 These can be 
aliphatic (e.g., 1,6-hexamethylene diisocyanate, HDI), cycloaliphatic (e.g., isophorone diisocyanate, 
IPDI), dicycloaliphatic (e.g., 4,4′-dicyclohexylmethane diisocyanate, HMDI), polycyclic or aromatic 
(e.g., toluene diisocyanate, TDI, or more commonly, 4,4′-methylene diphenyl diisocyanate, MDI). 
The isocyanate reactivity is governed by the positive character of the NCO carbon atom, which is 
susceptible to attack by nucleophiles, and oxygen and nitrogen by electrophiles.18 In aromatic 
diisocyanates, the negative charge becomes delocalised onto the ring and hence these molecules are 
more reactive than their aliphatic counterparts.8 The choice of isocyanate for PU production is 
governed by the properties required for end-use applications. To prepare rigid PUs, aromatic 
isocyanates are chosen, however, PU derived from these isocyanates show lower oxidative and 
ultraviolet stabilities than aliphatic diisocyanates, which are also more expensive.18 A key property of 
isocyanates is their NCO content, this typically being 23-48%.19 
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Fig. 1. Reaction of a common diisocyanate (MDI) with a polyol to form a PU, with the idealised 
structure, dimer and urethane linkage shown. 
 
 
Polyols 
 
The polyol component usually comprises of polyesters, polyester polyols (PEP), polycaprolactones 
(PCLs), polycarbonates or polyethers. Polyesters, introduced between 1937 and 1956, have better 
solvent, abrasion and cut-resistance, although are susceptible to hydrolytic degradation.20 Polyethers, 
introduced in 1956, are more commonly used, although tend to suffer from oxidative degradation. 
Three common types are polyethers are used: polypropylene glycols (PPGs), polyethylene glycols 
(PEGs) and polytetramethylene ether glycol (PTMEG), the latter of which is made from 
polymerisation of tetrahydrofuran (THF) and is used in high-performance coatings and in wetting and 
elastomer applications. PUs produced from PTMEGs tend to have the best physical, higher resilience, 
hydrolytic stability and dynamic properties.21 There are more than 500 commerically available polyols 
and with a much reduced set of available isocyanates, it is the polyols that fundamentally determine 
the final PU properties.22  
 
Branching in PEPs also dramatically change PU properties: high-branched PEPs produce rigid PUs 
with good chemical and thermal resistance, whereas, less branched PEPs produce flexible PUs with 
inferior chemical resistance.18 Flexible PUs also results from using polyols with high molecular mass 
and vice versa.18   
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Chain extenders 
 
Chain extenders are usually short-chain diols added during the PU polymerisation process that further 
modify the properties of the resultant PU.23 A typical example is 1,4-butanediol (BD), and this has 
been shown to produce hard segments within the resultant PU. Other difunctional, low molecular 
mass diols, cyclohexane dimethanol, diamines, hydroxylamines (diethanolamine and triethanolamine) 
are also sometimes used as chain extenders. Glycerol is another commonly used extender, with the 
advantage of producing a crosslinked structure owing to it having three OH groups per molecule; this 
increases thermal stability in the PU. 
 
PU catalysts 
 
PUs can be synthesised in the presence or absence of a catalyst, although the former is more common. 
Catalysts play a key role in controlling the reaction kinetics, reducing curing temperatures and 
durations, and are very often responsible for the preferred polymerisation reaction taking place.24 
Catalysts used for synthesising PUs have included bismuth, butyl tin trichloride, titanium 
tetrachloride, ferric chloride, antimony trichloride, cadmium nitrate, cobalt benzoate, aluminium 
oleate, diphenyl mercury, zinc naphthenate, zirconium naphthenate and molybdenum.25 Obviously, a 
number of these are toxic and have now been withdrawn under legislation placed on industry, such as 
that of RoHS26 and REACH27 regulations. Tin catalysts are often now used for manufacturing 
prepolymers and amines (strong bases, e.g., diaminobicyclooctane, DABCO) for the reaction of 
polyols and isocyanates.19 
 
PU properties 
 
PUs are made up of alternating soft and hard segments (Fig. 2a)28 The soft segments are dependent on 
the long-chain diol providing elasticity and low temperature resistance to the polymer.20,28-30 The hard 
segments are thought to be due to the reaction between the chain extender, often a low molecular 
weight diol, and the diisocyanate producing hydrogen bonding involving urethane links and provides 
the extra strength.28,30,31 These hard segments are responsible for crystalline regions, modulus, upper-
use temperature, tear strength and hardness of PU.29 
 
Change in the chemical composition (monomer/raw materials, functional group number), ratio of 
hard-to-soft segments or molecular mass result in a range of different polymer properties and 
hardnesses.30 For example, urethane groups have high polarity, hence, a larger density of urethane 
groups increases polarity producing a rigid, hard PU product at room temperature. 
 
While most PUs are not thermosets (cannot be processed, melted and then re-processed), 
thermoplastic PUs (TPUs) are readily available. In these polymers, there is a strong attraction between 
the hard segments due to the high polarity, resulting in a high degree of aggregation and order in this 
phase, displayed as crystalline or apparent crystalline areas, often referred to as fixed phase.31 The 
hard segments are partially separated from the soft segments: this is often referred to as phase 
separation (Fig. 2b).32 The degree of phase separation and its effect depends on the difference between 
the molecular mass and polarity of the two segments. This is because, as described by Michael 
Szyycher,29 dipole-dipole interactions and hydrogen bonding provide a pseudo-cross-linked network 
structure between linear PU chains creating a polymer with the physical characteristics and 
mechanical behaviour of a covalently crosslinked network. Hydrogen bonds can also form between N 
– H and C = O groups, either within hard segments, soft segments or bridging the two.33 Hydrogen 
bonding in the hard phase between the urethane bonds creates a physical crosslinking point, 
preventing polymer deformation due to chain slippage. Three-dimensional crosslinking can be 
achieved when multifunctional components such as triisocyanates or branched hydroxyl polyols are 
used.34 The percentage crystallinity can be anywhere in the region of 0-13%, with a fully crystalline 
PU having a density of 1.322 g cm-3 at 20 °C. 
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Fig. 2. Idealised structure of PU depicting the origin of formation of hard and soft segments (a) from 
chain alignment of isocyanates and presence of non-aligned, long-chained polyols (b), respectively. 
 
 
Numerous factors affect the degree of phase separation, such as polarity of functional groups, 
molecular mass, molecular mass distribution, crosslinking density, chemical structure of PU chains, 
size of the hard and soft segments and even the technique used to shape the final product.34 
 
Biomedical applications of PU 
 
PUs offer one of the most diverse classes of materials.18 Their uses span from flexible foam in 
upholstered furniture, rigid foam in insulation of walls and roofs, thermoplastic PU used in medical 
devices, to coatings, elastomers, adhesives and sealants used on floors and automotive interiors.18 PUs 
are unique, offering the elasticity of rubber combined with the toughness and durability of metal. 
These polymers are available over an extremely broad hardness range  (eraser-soft to bowling-ball-
hard).16 Vast improvements in down-time, maintenance time and costs have resulted from PU 
replacing tranditionally used materials.35 The remainder of this review highlights recent (2014-2017) 
reported biomedical uses of PU coatings and materials.  
 
PUs, unlike many other synthetic and natural biodegradable polymers, have mechanical and physical 
properties comparable to natural tissue.36  This, matched with low platelet adhesion and in vitro 
protein adsorption allows many uses of PU in the biomedical industry.34 Critically, consideration of 
the biodegradation of PUs, as with other biomaterials, needs to be considered. Tailoring these 
properties, in the case of PUs, can be easily achieved through variation of the chemical composition, 
ratio of hard-to-soft segments and the molecular mass. Generally, the rate of PU biodegradation is 
mainly dependent on the soft segment structure, which is controlled by the polyol chemistry.36 This is 
in keeping with the observation that PUs with amorphous structures degrade more rapidly than those 
with semi-crystalline segments, since they allow permeation of water through the amorphous regions. 
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PPGs, PEGs, PCLs and glycolic acid are common polyols used in biodegradable PUs. Nontoxic 
degradation products are one of the main attractions in PEGs as well as hydrophilicity, solubility in 
water and organic solvents and absence of antigenicity and immunogenicity. PCLs also produce 
nontoxic degradation products, although are often more hydrophobic and so reduce degradation rates. 
Increasing this property can be affected through the introduction of hydrolysable chain extenders into 
the hard segments. BD, 1,2-ethanediamine and 1,2-ethanediol are often used as chain extenders. Both 
aromatic and aliphatic diisocyanates are used in making biodegradable PU systems, although the 
former (e.g., TDI and MDI) have been found to degrade into toxic by-products and are being replaced 
with aliphatic diisocyanates (e.g., IPDI and HDI). 
 
Some specific and recent biomedical applications of PU are detailed below. 
 
Antibacterial surfaces and catheters 
 
Jiang et al. used novel amphiphilic poly(dimethylsiloxane)-based PU networks tethered with 
carboxybetaine to achieve an antibacterial efficiency of 97.7% and possessed anti-adhesive properties, 
demonstrating great potential for biomedical devices and in marine applications.20 Substitution of the 
polyol with chitosan, a biocompatible polysaccharide isolated from crustaceans and fungi, led to a PU, 
adsorbed onto sterilised discs, that showed improved E. coli inhibition compared to chitosan alone.37 
Chitosan and heparin (the latter having a high negative charge that repels negatively charged bacteria) 
have been immobilised onto the surface of PU in a stepwise process to produce an antibacterial layer 
resistant to Staphylococcus aureus, S. epidermidis, E. coli and Pseudomonas aeruginosa.38  Cu and 
Ag nanoparticles have been incorporated into the polyol component (PTMEG 1000) and then reacted 
with the isocyanate (MDI) with a BD extender; the resultant PUs showed no toxicological issues and 
exhibited the desired antimicrobial activity suitable for medical applications.39 Zanini et al. coated PU 
catheters with 3-(trimethoxysilyl)-propyldimethyloctadecylammonium chloride in a multistep process 
that involved a vapor phase plasma-induced graft polymerisation of acrylic acid;40 the coated catheters 
exhibited antimicrobial activity against E. coli (Fig. 3). A review of recent advances in antimicrobial 
coatings for urinary catheters appeared in 2017;41 the authors list the advantages and disadvantages of 
various polymers, including PU, advantages of which include toughness, biocompatibility, 
haemocompatibility and ease of processing. The review describes a number of coated PU materials 
with antibacterial properties, such as a salicylic acid-releasing PU coating,42 with resistance against P. 
aeruginosa and E. coli, and an N-halamine generating coating grafted onto PU which could be 
regenerated for long-term use.43 
 
 
 
Fig. 3. FTIR (attenuated total reflectance) and photographs of acrylic acid modified (left picture) and 
untreated PU catheter after silanisation and treatment with bromophenol blue to confirm the presence 
of the acrylic acid coating. This coating exhibited in vitro antimicrobial activity against E. coli.40 
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Drug delivery vehicles 
 
The chemotherapy drug gefitinib has been embedded between PU support and top layers using spray 
coating to form a drug-eluting stent for bronchotracheal cancer;44 when the drug was embedded as 
crystals, release was recorded for 7-21 days, but when embedded into poly(lactic-co-glycolic acid) 
(PLGA) microspheres, a sustained release >6 months was noted (Fig. 4). Solanki and Thakore have 
modified PU with acid chain extenders to impart swelling controlled drug release properties and PU 
pH-responsive characteristics; release of felodipine (a model drug) was faster at pH 7.4 than gastric 
pH 1.2, offering targeted delivery for the colon.45 PU-based (polyesterurethane) nanoparticles, 
containing indomethacine (an anti-inflammatory drug) have been embedded in a surface polymeric 
(gelatin) layer on a composite shell scaffold (bioactive glass/hydroxyapatite);46 a sustained drug 
release was observed and the biocompatibility was not compromised. Campiñez et al. synthesised 
new biodegradable PUs, containing disulphide bonds, and studied their ability to be used as sustained 
release excipients for delivery to the colon.47  
 
The stability of PurSil®AL20 (PUS), a copolymer of HMDI, BD, poly(tetramethylene oxide) 
(PTMO) and poly(dimethylsiloxane) (PDMS), for use as a vehicle for docetaxel delivery through an 
oesophageal drug eluting stent (DES) was investigated by Shaikh et al.;48 solid-state behaviour of 
docetaxel and polymer microstructure were found to affect drug release. Da Silver et al. report the 
successful incorporation or borage oil (containing essential fatty acids for wound healing) into and its 
release from PU foam wound dressings; the authors also review many other drugs that have been 
incorporated into such dressings, e.g., analgesics, cicatrizing agents, antibiotics and anti-cancer 
drugs.49 
 
Electrospun PU-dextran nanofibre mats have been loaded with estradiol (the most bioactive 
endogenous estrogen) to improve cutaneous wound repair in post-menopausal women;50 the 
electrospinning process directly blends the PU and dextran polymers to obtain the optimum physical 
and biological properties of the fibres. Electrospinning was also used to make a nanofibre composite 
PU-Eudragit acrylic polymer mat in which the pH dependent release of paclitaxel was investigated;51 
the acrylic polymer allowed release of the drug in the duodenum (mean pH 5.4). Smart sensitive 
polymers, designed to change properties based of environmental conditions (pH sensitive in this case), 
have been prepared from PU-N,N-diethylaminoethyl methacrylate hybrids, with rhodamine 6G added 
as a model drug;52 loading methods and release mechanisms were discussed. Graphene nanoparticles 
have been dispersed into incorporated into PTMEG and reacted with HMDI, with BD extender, to 
produce a PU with greater toughness and storage modulus than without the inclusion;53 controlled 
release of an incorporated drug (tetracycline hydrochloride, an antibiotic) was also more sustained 
than with PU alone that had a burst release.  
 
Stents 
 
PU stents comprising an Auxetic (rotating-squares) geometry (to reduce migration/misplacement) for 
use in palliative treatment of squamous cell carcinoma of the oesophagus have been manufactured 
using a variety of techniques; laser-cutting of vacuum casted steamless stents were favoured.54 Aguilar 
et al. describe a thermoresponsive matrix incorporating nanofibres in PU for a non-vascular nitinol 
stent alternating that uses an alternating magnetic field for hyperthermia therapy;55 5-fluorouracil 
and/or paclitaxel were simultaneously released. Polyethyleneimine (PEI) brushes have been grafted 
onto PU ureteral stents to help prevent host tissue inflammation and blockage;56 further alkylation of 
the brushes led to enhanced antibacterial activity. PU stents are being used in infants and children 
with Kawasaki disease, a multisystem inflammatory disease that is the most common cause of 
acquired heart disease in children;57 the thick (90 μm) PU membrane electrospun around an Orsiro 
stent had the most desirable stretching properties. 
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Fig. 4. (a) Release of tumour suppressing drug gefitinib from PU constructs loaded with gefitinib-
PLGA microspheres; (b) schematic of bronchotracheal stent to provide long-term release of this 
drug.44 
 
 
Surgical dressings/pressure sensitive adhesives 
 
PUs have superior properties to many other polymers for use as pressure sensitive adhesives (PSAs); 
these materials provide good adhesion to substrates, such as skin, with only slight finger pressure and 
hence are commonly used for surgical dressings.58 Breathability and adhesion strength in these 
materials have been improved using different crosslinkers by Singh et al.58 PU-dressing foams offer 
excellent water absorption, optical mechanical properties and cost effective, but have low bioactivity 
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and poor healing capability; incorporation of bioactive silica nanoparticles during the sol-gel process 
improved wound-closure rates and accelerated collagen and elastin fibre regeneration.59 Morgado et 
al. also reported a modified crosslinked PU hydrogel, which absorbed large quantities of water 
without dissolving. This property is useful for wound healing dressings where an asymmetric 
membrane made of a PEG polyol prevents the rapid dehydration of the wound surface and penetration 
of bacteria. Platelets are attracted to this layer due to its hydrophilic character, which generates the 
coagulation cascade.60 
 
Tissue engineering scaffolds and electrospinning 
 
Electrospinning has been used to combine PU with the propolis (a resinous substance, with a variety 
of medical properties, produced by bees) to make tissue scaffolds;61 i.e., a material that mimics the 
extra cellular matrix (ECM), offering temporary support for cell growth, migration and tissue 
regeneration (Fig. 5). The resultant mats exhibited antibacterial activity and enhanced 
cytocompatibility/cell viability, showing promise for use in wound dressings and skin tissue 
engineering. A review comparing electrospinning and microfluidic spinning approaches to producing 
micro- and nanofibres appeared in 2017;62 the paper reports PU fibres being used in tissue engineering 
of dense tissues, and ECM generation of human ligament fibroblasts on a PU nanofibre matrix. 
Segmented PUs (SPUs), based on PEG, poly(L-lactide) and poly(trimethylene carbonate) blocks and 
using an aliphatic diisocyanate, were electrospun into fibrous scaffolds;63 novel biodegradable 
elastomeric highly porous matrices showing promise for soft tissue engineering were produced. In a 
2015 review by Janik and Marzec, the use, methods of fabrications, relative merits and latest 
developments of PU foam systems for scaffolds are presented.64 Cardiac cell proliferation on PU 
nanofibrous mats produced by blow spinning was found to be superior to that of polystyrene and 
hence could form a better in vitro model for the study of cardiac drugs than the current use of 
polystyrene.65 
 
 
 
Fig. 5. SEM (field-emission) images of PU fibres obtained from (a) 0, (b) 5, (c) 10 and (d) 30 wt% 
propolis-containing PU solution. Inserts show corresponding water contact angles.61 
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Fig. 6. Schematic showing process of thermoplastic PU nanocomposite fabrication for potential cell 
therapy and tissue engineering applications.66 
 
 
Shahrousvand et al. included iron oxide nanoparticles into PU for tissue engineering applications (Fig. 
6);66 a variety of techniques were used to characterise the films produced, including atomic force 
microscopy (AFM) to measure surface roughness.  
 
PU modified with ascorbic acid (vitamin C) has been investigated as a material for regenerative 
medicine of soft tissue, owing to the known wide influence of the inclusion on tissue regeneration;67 
haemocompatibility tests were successful and the films were sensitive to S. aureus, P. aeruginosa and 
E. coli. 
 
Marzec et al. recently produced a review of recent developments on the use of PU in bone tissue 
engineering;68 PUs are particularly attractive for such applications owing to their ability to calcify, 
support cell adhesion and proliferation of human osteoblast cells,69 in addition to their non-toxic and 
tailorable mechanical properties.     
 
Nerve regeneration 
 
A highly tunable conductive polymer (aniline pentamer) with PU has been constructed that enhances 
myelin gene expression and neurotrophin secretion necessary for peripheral nerve regeneration.70 
Polymer mats made from a PU-polylactide (PLA) blend for connecting broken nerve tracks using 
olfactory-bulb glial cells and mesenchymal stem cells were studied by Grzesiak et al.;71 glial cells on 
pure PU exhibited altered morphology, but the blended polymer showed optimal properties (Fig. 7). 
Using a 3d-printing system, Hsieh et al. successfully embedded neural stem cells into biodegradable 
PU gels;72 these could then be injected into zebrafish to restore an impaired nervous system.  
 
Cardiac patches 
 
Reduced ventricular contractile function often results when scar tissue replaces cardiomyocytes 
following myocardial infarction (MI).73 These cells have been cultured onto nanocomposite scaffolds 
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of Au nanotubes/nanowires incorporated into biodegradable, nano-porous PU;73 electrical stimulation 
was also successful in producing cell-cell interaction, as was key myocardium gene expression. 
D’Amore et al. used a bilayer patch consisting of a cardiac ECM-enriched layer containing sparse, 
microporous, biodegradable poly(ester carbonate urethane)urea, PECUU) and an upper microporous 
PECUU layer;74 reduced scar formation, reduced ventricle thinning and a promotion in angiogenesis 
were observed. 
 
PU coatings for breast implants 
 
PU foam coatings for silicone breast implants were first developed in the 1970s as a method of 
reducing capsular contracture.75,76 The PU coating is designed to break down and becomes part of the 
capsule and prevents alignment of myofibroblast cells, interrupting the strength required for capsular 
contracture.77,78 A link between PU and the carcinogen 2,4-toluenediamine (TDA) was made in 
1991,79 however, which led to a ban on such coated implants in the US and UK. A systematic review 
by Duxbury & Harvey in 2016 concluded that PU implants should be considered a safe alternative to 
textured silicone implants.80 
 
 
Fig. 7. Olfactory bulb glial cells (after 7 days) on PU (row A), PU/PLA blend (B), pure PLA (C) and 
polystyrene control (D); dyes: red + white (p75 + nuclear, respectively, column 1), green + white 
(actin + nuclear, respectively, 2) and SEM (3); scale bars = 200 µm.71 
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Concluding remarks 
 
PUs are an exciting class of polymeric materials that exhibit a variety of properties that make them 
desirable for use as coatings and bulk materials in numerous applications in the biomedical sector. 
Examples include antibacterial surfaces and catheters, drug delivery vehicles, stents, surgical 
dressings/PSAs, tissue engineering scaffolds and electrospinning, nerve generation, cardiac patches 
and PU coatings for breast implants. This review has concentrated on recent literature from 2014; for 
earlier biomedical application of polymer coatings studies, readers are directed to a previous review in 
this journal.81 
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